An exploratory study of NS-304

A phase 2 exploratory study of NS-304 in Japanese pediatric patients with pulmonary arterial hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225295

Enrollment

Registered

2020-07-30

Start date

2020-11-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension

Interventions

investigational material(s) Generic name etc : NS-304 INN of investigational material : Selexipag Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with PAH diagnosis confirmed by right heart catheterization

Exclusion criteria

Exclusion criteria: Patients with severe or moderate hepatic impairment etc.

Design outcomes

Primary

Measure	Time frame
efficacy Plumonary vascular resistance index	—

Secondary

Measure	Time frame
efficacy Pulmonary hemodynamics	—

Countries

Japan

Contacts

Public ContactClinical Development Operations

Nippon Shinyaku Co., Ltd.

zz_mail_clinical-trials@po.nippon-shinyaku.co.jp+81-120-40-8930

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026